Theranostic Trials

Ovarian

Adrenal Gland/AdrenocorticalBasket Trials (Multiple Types)Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI)Bladder/Urothelial (GU)Bone MetastasesBrain and Central Nervous System (CNS)BreastCervical (GYN)Colon/Rectal/Anal (GI)Endocrine CancersEndocrine NeoplasiaEsophageal (GI)Gastric/Stomach (GI)Gastrointestinal (GI) (Multiple Types)General Solid Tumors (Multiple Types)GenitoUrinary (GU) (Multiple Types)GEP-NET (NEC)GI Stromal Tumor (GIST)Gynecologic (GYN) (Multiple Types)Head and Neck CancersHepatocellular/Liver (GI)Hodgkins LymphomaInsulinomaKidney/Renal Cell Carcinoma (GU)LeukemiasLungLymphomasMelanoma/Skin CancersMesotheliomaMultiple MyelomaNeuroBlastomaNeuroEndocrine (NEC) (Multiple Types)NeuroEndocrine Carcinoma (NEC)OsteosarcomaOvarianOvarian/Primary Peritoneal (GYN)Pancreatic (GI)Paraganglioma (NEC)Penile (GU)Pheochromocytoma (NEC)PituitaryProstate (GU)Salivary GlandSarcomaSynovial CarcinomaTesticular (GU)ThymomaThyroidUnknown Primary CancersUterine (GYN)Vulvar (GYN)

Study Status

Enrolling
On Hold
Not Enrolling
Unknown

Last Updated: Mon Dec 16 2024

Pharmaceutical Trials (Site Sponsors)

Investigator Trials

Pharmaceutical & Investigator Trials (Non-Site Sponsors)

NCT05856409

Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence

This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.

🇺🇸

NCT06503146

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in certain cancer cells. [18F]FAPI-74 is a new tracer-a substance that is injected into a person s body before an imaging scan. Researchers believe that [18F]FAPI-74 may be able to highlight FAP enzymes more effectively than approved tracers. If so, the new tracer would make it easier to find FAP-positive tumors in the body.

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468